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The therapeutic potential of monoclonal antibodies
for treating a variety of severe or life-threatening dis-
eases is high. Although intravenous infusion appears
the simplest and most obvious mode of administra-
tion, it is not applicable to many long-term treat-
ments. It might be advantageously replaced by gene/
cell therapies, however, rendering treatments cost-
effective and eliminating the short- and long-term
side-effects associated with injection of massive doses
of antibodies. We have tested whether skin can
potentially be used as an organ for production and
systemic delivery of ectopic antibodies. Normal
human primary keratinocytes were shown to be cap-
able of synthesis and secretion of a model monoclo-
nal antibody directed against human thyroglobulin
upon retroviral gene transduction in vitro. Neo-
epidermis reconstructed in vitro, either in cell culture
inserts or on dermal substrates, from such modi®ed
keratinocytes also produced the monoclonal anti-
body. Interestingly, the latter could cross the epider-
mis basal layer and be released in culture ¯uids.
Finally, grafting of epidermis reconstituted in vitro on
dermal substrates to SCID mice permitted sustained
monoclonal antibody delivery into the bloodstream
to be achieved. Our data thus show that genetically
engineered keratinocytes can potentially be used for
genetic antibody-based immunotherapies. They also
indicate that proteins as big as 150 kDa, after release
by engineered keratinocytes into skin intercellular
spaces, can migrate to the general circulation, which
is potentially important for a number of other gene-
based therapies. Key words: cell therapy/gene therapy/
keratinocyte/monoclonal antibodies/skin. J Invest Dermatol
118:288±294, 2002
T
he potential of therapeutic applications of monoclonal
antibodies (MoAb) for treating pathologic manifesta-
tions as varied as cancer, viral infections, transplant
rejection, cachexia, neuropathologies, autoimmune
diseases, etc., is high (Chester and Hawkins, 1995).
The actual therapeutic value of MoAb has recently been illustrated
by ef®cient injection-based treatment of non-Hodgkin's lympho-
mas (Grillo-Lopez et al, 1999; Maloney, 1999), acute myelogenous
leukemia (Cheson et al, 2000), breast cancers (Baselga, 2000a;
2000b), acute rejection in renal transplantation (Ekberg et al, 2000;
Thistlethwaite et al, 2000), Crohn's disease (Present et al, 1999;
Assche and Rutgeerts, 2000), and rheumatoid polyarthritis (Maini
et al, 1999; Markham and Lamb, 2000). Along the same line, a total
of eight MoAb have now been approved by the US Food and Drug
Administration for clinical use and more than 70 MoAb are
currently in clinical trials beyond phase I and phase II (Glennie and
Johnson, 2000).
In theory, intravenous injection is the simplest and most obvious
mode of administration of puri®ed antibodies to patients. Though
satisfactory for short-term treatments, however, it is often not
applicable for long-term treatments (which might involve up to
grams of antibody per month and per patient for treating certain
diseases) due to the restrictive cost of proteins produced in vitro and
certi®ed for human application. Moreover, many technical prob-
lems posed by industrial mass production have not yet been solved
and still limit the availability of therapeutic antibodies. In addition,
hour-long infusions require specialist expertise to administer and
are often associated with mild to very severe side-effects. The latter
can include vomiting, migraines, anemia, and thrombocytopenia
and, in certain cases, coma or even myocarditis infarction (Maloney
et al, 1997; McLaughlin et al, 1998; Soykan et al, 2000). In other
words, the large-scale clinical application of a number of MoAb ±
some with an already demonstrated therapeutic activity ± is
currently impossible or severely compromised. The in vivo pro-
duction of therapeutic antibodies, after either genetic modi®cation
of the patients' own cells or implantation of exogenous antibody-
producing cells, might thus advantageously replace regular intra-
venous injection by a single-step year-long treatment rendering
long-term therapeutic antibody treatments cost-effective and
eliminating side-effects associated with the infusion of large
quantities of antibodies. In addition, continuous and sustained
delivery of antibodies at a low, but therapeutic, level should also
suppress, or at least delay, the onset of neutralizing anti-idiotypic
immune responses, which can develop when massive doses of
puri®ed immunoglobulins are repeatedly injected into humans or
animals (Isaacs, 1990; Kuus-Reichel et al, 1994).
As a ®rst step to the development of antibody-based gene/cell
therapies, we have shown the technical feasibility of month- to
year-long in vivo production and systemic delivery of MoAb in the
mouse, as an animal model, using the grafting of genetically
modi®ed myoblasts (NoeÈl et al, 1997) and skin ®broblasts (NoeÈl et al,
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2000) and the implantation of antibody-producing cells encapsul-
ated in a matrix of cellulose sulfate (Pelegrin et al, 1998a, 2000).
Interestingly, in no case was an anti-idiotypic response against the
ectopic antibody detected (Pelegrin et al, 1998b; Noel et al, 2000).
More recently, we have validated the therapeutic value of this
novel therapeutic approach by ef®ciently protecting mice that were
lethally infected with a neurodegeneration-inducing retrovirus by
implantation of cellulose-sulfate-encapsulated cells producing a
virus-neutralizing antibody (Pelegrin et al, 2000).
Plasmocytes, which are the cells naturally specialized in antibody
production, cannot be used for long-term genetic antibody-based
therapies because they already secrete an antibody and are short-
lived (half-life of a few days). Towards the aim of human
application, a major issue is thus to identify tissues amenable to
genetic modi®cation for MoAb production and persisting for
virtually the whole patient's life after grafting. Skin is obviously a
good candidate for this purpose because (i) it is the most accessible
tissue, (ii) keratinocytes can easily be expanded ex vivo, (iii) they can
be transduced by retroviral vectors, (iv) normal human epidermal
primary keratinocyte (NHEPK) populations contain stem cells with
a high replicative potential (Barrandon and Green, 1987; Jones and
Watt, 1993; Tani et al, 2000; Watt, 2000; Watt and Hogan, 2000),
(v) skin grafts can persist long-term, as is well established in the
treatment of burn victims, (vi) ef®ciency of skin grafting can be
monitored by direct visual examination, (vii) keratinocytes have a
high protein secretion potential as evidenced from strati®ed
cultures (see Katz and Taichman, 1999; Cao et al, 2000), (viii)
skin has already been demonstrated to be capable of systemic
delivery of ectopic proteins though the latter were of small size
(Fenjves et al, 1989; 1994; Teumer et al, 1990; Gerrard et al, 1993;
Barra et al, 1994; Eming et al, 1998; Meng et al, 1998; Sawamura et
al, 1998), and (ix) we have previously shown that the A431
keratinocytic cell line can produce MoAb showing the same
thermodynamic and kinetic properties as the parental antibody
produced by B cells in vitro (NoeÈl et al, 1997). Supporting the idea
that engineered skin can potentially be used for antibody-based
therapies, we report here the in vivo production and systemic
delivery of a model MoAb directed against human thyroglobulin in
an experimental setting consisting of the grafting to SCID mice of
human epidermis reconstituted in vitro from genetically modi®ed
keratinocytes.
MATERIALS AND METHODS
Retroviral vector, retrovirus-producing cell lines, and Tg10-
MoAb-producing keratinocytic cells The Tg10-antibody-expressing
PM130 (NoeÈl et al, 1997) and the CD167 (NoeÈl et al, 2000) retroviral
vectors were derived from the MoMuLV-based pLXPXSN (Morgan et
al, 1992) and Akv-derived ptv-Akv-tRNApro (Lund et al, 1993) plasmids,
respectively. PA130.2 (NoeÈl et al, 1997) and FlyA167.1 (NoeÈl et al,
2000) are retrovirus-producing cell lines derived by transfection of
PM130 and CD167 into PA317 (Miller and Buttimore, 1986) and FlyA
(Cosset et al, 1995) amphotrophic packaging cell lines, respectively.
PA96.7 cells produce the void pLXPXSN vector, used as a negative
control in our experiments, and are derived from PA317 helper cells. All
cell lines were cultured in Dulbecco's modi®ed Eagle's medium
(DMEM) (Gibco BRL, Grand Island, NY) containing 10% fetal bovine
serum (FBS). Conditions for retrovirus production and assay have been
described elsewhere (NoeÈl et al, 1997). Titers of retroviral supernatants
were estimated to be 104 colony-forming units (cfu) per ml on NIH
3T3 ®broblast cells for the PA130.2 and FlyA167.1 cell lines and 105 cfu
per ml for the PA96.7 cells. A431.130.2 cells were obtained by
transfection of PM130 into A431 keratinocytic cells (NoeÈl et al, 1997)
and were grown in RPMI 1640 medium (Gibco BRL) containing 10%
FBS.
Cultures and retroviral infection of human epidermal primary
keratinocytes NHEPK were freshly prepared from human neonatal
foreskins. Brie¯y, foreskins were placed in Ca2+- and Mg2+-free
phosphate-buffered saline (PBS; 150 mM NaCl, 10 mM Na3PO4 pH 7)
containing 20 mg per ml of gentamycin (Gibco BRL) for 1 h. They
were then incubated in the presence of 25 U per ml of dispase (Gibco
BRL) at 4°C for 18 h and the epidermal layer containing the
keratinocytes was peeled off from the dermis using forceps. Cell
dissociation was obtained through three serial 5 min treatments at 37°C
with a solution containing 0.05% trypsin and 0.53 mM ethylenediamine
tetraacetic acid (EDTA) (Gibco BRL) under gentle agitation in a humid
atmosphere with 5% CO2. Trypsin activity was blocked by addition of
FBS and cells were gently resuspended in low calcium de®ned
keratinocyte serum-free medium (DK-SFM) (Gibco BRL), supplemented
with 15 ng per ml epidermal growth factor (Sigma, St. Louis, MO) ®nal,
100 mg per ml streptomycin, and 100 U per ml penicillin. The culture
medium was changed every 2±3 d until cells reached 80% con¯uence, at
which point they were passaged. For retroviral gene transfer, four rounds
of infection were carried out in the presence of 8 mg per ml polybrene
(Sigma) for a period of 2 d in 60 mm diameter dishes using keratinocytes
passaged twice and cultured to 50%±60% con¯uence. Typically, for each
round of infection, 105 cells were placed in the presence of 1.5 ml of
cell culture supernatant containing 104 infectious viruses at 37°C for 2 h,
which means a multiplicity of infection of 0.15. Then, the medium was
replaced by 3 ml of complete DK-SFM for further culture. As ef®ciency
of infection by all three vectors could not be assayed directly after
infection of keratinocytes, we resorted to an indirect assay. Duplicates of
keratinocyte cultures were infected in parallel experiments with culture
supernatants containing 0.5 3 104 cfu of a b-galactosidase-expressing
amphotropic retroviral vector produced by the FlyA packaging cell line
(Marin et al, 1996) plus 0.5 3 104 cfu of either PM130, CD167, or
pLXPXSN vectors. Two days after the last infection round, keratinocytes
were stained for b-galactosidase activity (Marin et al, 1996; Bachrach et
al, 2000) and blue plaques were scored for calculation of the ef®ciency of
transduction.
Preparation of dermal substrates Dermal substrates were prepared
from normal human adult skin samples obtained from healthy volunteers
undergoing plastic surgery after informed consent. For de-
epidermization, skin specimens were heated at 56°C in 20 mM EDTA-
containing PBS for 5 min and immediately transferred onto ice where
epidermis was peeled off with forceps. De-epidermized dermis (DED)
were placed into sterile cryotubes and morti®ed through 10 rounds of
freezing and thawing in liquid nitrogen as described elsewhere (ReÂgnier
et al, 1981). DED were stored at ±80°C until use.
Epidermal cultures Epidermis was reconstructed either on dermal
substrates or on membrane inserts according to the well-established
techniques of PrunieÂras et al (1983) and Rosdy and Clauss (1990),
respectively. Cultures were performed in PR culture medium, which
consists of 66% DMEM, 22% Ham F12, 10% FBS, 8.4 ng per ml
cholera toxin (Sigma), 400 ng per ml hydrocortisone (Sigma), 20 ng per
ml epidermal growth factor (Sigma), 5 mg per ml insulin (Sigma),
1.5 mM CaCl2, 1% non-essential amino acids (Gibco BRL), and 10
±6 M
L-isoproterenol; the medium was changed every 2 d. For culture on
membrane inserts, 3 3 105 NHEPK were seeded per culture well (Font
et al, 1994) in the presence of 300 ml of PR medium in both the lower
and the upper culture cell compartments. After 5 d, the upper phase
culture medium was removed and NHEPK were further cultured at the
air±liquid interface for the rest of the experiment. For culture on dermal
substrates, 3 3 105 NHEPK, in a volume of 15 ml, were dropped on
morti®ed DED, dermal side down, and cultured at the air±liquid
interface. In both cases, fully reconstituted epidermis was obtained within
15 d of culture.
Immunoassay and immunohistochemistry analysis The Tg10
antibody was assayed in culture supernatants and mouse sera by enzyme-
linked immunosorbent assay (ELISA) as described by Piechaczyk et al
(1985) and NoeÈl et al (Piechaczyk et al, 1985; NoeÈl et al, 1996, 1997).
Human thyroglobulin (hTg) for coating plates was from Biogenesis
(Poole, U.K.). Tg10 antibody puri®ed to homogeneity from hybridoma
supernatants was used as a standard. Immunohistochemical detection of
Tg10 in human epidermis regenerated on dermal substrates was
performed as follows: after 15 d in culture, reconstituted tissues were
collected and embedded in OCT (Tissue-Tek, The Netherlands), frozen
in liquid nitrogen, and stored at ±80°C until use. Cryostat sections
(7 mm) were prepared and ®xed in 3.7% paraformaldehyde for 15 min,
rinsed three times with PBS, and stored at ±80°C or immediately
processed for immunostaining at room temperature. They were treated
with acetone for 20 s, rinsed three times in PBS, placed in PBS solution
containing 1% bovine serum albumin (Sigma) for 30 min, incubated in
PBS solution containing FITC-conjugated goat anti-mouse IgG and 1%
Tween-20 for 30 min, and ®nally washed three times in PBS solution
containing 1% Tween-20. Slides were mounted in DAPI-containing
Vectashield (Biovalley, Marne la ValleÂe, France) before microscopic
examination.
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Skin grafting to SCID mice Grafting of retrovirally transduced and
regenerated epidermis was performed subcutaneously as previously
described (Levy et al, 1998) using 10±12-wk-old CB17/SCIDbg mice
(Harlan, Gannat, France) as recipients. Brie¯y, mice were anesthetized
using 0.01 ml per g of body weight of a solution containing 0.1%
xylasine (Rompun, Bayer, Leverkusen, Germany) and 10 mg per ml
ketamine (ImalgeÁne, RhoÃne MeÂrieux, Lyon, France); two lateral
incisions through the skin were made on both sides of the spinal cord,
and reconstructed skin patches, dermis uppermost, were placed into a
subdermal space cleared above the underlying connective tissue. Mice
were bled for Tg10 antibody assay at regular intervals. Blood samples
were allowed to clot and serum was recovered after centrifugation at
8000 3 g for 10 min at room temperature. Serum aliquots were stored
at ±20°C until use.
RESULTS AND DISCUSSION
NHEPK can make and secrete antibodies We have
previously shown that genetically engineered A431 human
keratinocytic cells can produce antibodies (NoeÈl et al, 1997). It
was next important to determine whether primary keratinocytes
could do it as well. To this aim, foreskin NHEPK were retrovirally
transduced for expressing a MoAb, the production of which was
subsequently assayed in supernatants of cells cultured under either
proliferation-favoring (DK-SFM) or differentiation/strati®cation-
favoring (PR medium) conditions. The model MoAb (Tg10) was a
mouse IgG1/k directed against human thyroglobulin (Piechaczyk
et al, 1985), which we formerly cloned and functionally
characterized (NoeÈl et al, 1996) and for which a highly sensitive
ELISA is available (Piechaczyk et al, 1985).
Expression of retrovirally transduced genes can vary according to
the vector used and is sometimes, but not always, repressed in vivo
for yet-to-be-de®ned reasons (see Karavanas et al, 1998). This is
particularly true in the case of long tandem repeat (LTR)-driven
transcription as in vectors derived from MoMuLV, the parental
virus for most vectors used thus far. Therefore, to circumvent this
possible drawback, two different vectors were used in parallel in
our experiments. One was derived from MoMuLV (PM130; NoeÈl
et al, 1997) and the other from Akv (CD167; NoeÈl et al, 2000).
Although no major difference is seen in in vitro gene transfer
experiments between the two viruses, the latter is less ef®ciently
and less frequently repressed in vivo. In both vectors (i) transcription
was under the control of the viral LTR and (ii) Tg10 heavy and
light chains were translated from a monocistronic mRNA owing to
a poliovirus internal ribosome entry site cloned upstream of the
heavy chain. In both series of experiments, approximately 10% of
NHEPK were infected. Antibody production was observed both in
DK-SFM and in PR medium, with, however, a 2-fold better
production in the case of stratifying keratinocytes (Table I). This
situation is reminiscent of that of muscle cells where myotubes
were shown to produce ectopic MoAb 2- to 3-fold more ef®ciently
than myogenic cells (NoeÈl et al, 1997). The notion of possibly more
ef®cient antibody production by differentiated cells is also
supported by the fact that, when A431 cells, which are well
characterized non-differentiating keratinocytes, were retrovirally
transduced with PM130 (A431.130.2 cell line), they did not
produce more Tg10 when cultured in PR medium than when
cultured in DK-SFM (Table I).
In vitro reconstructed epidermis can produce the Tg10
MoAb As a next step, we investigated whether epidermis
reconstituted in vitro from genetically engineered NHEPK can
make and secrete an ectopic antibody. To this aim, we resorted to
two well-established experimental systems based on culture in cell
inserts (Rosdy and Clauss, 1990) and on dermal substrates
(PrunieÂras et al, 1983), which were tested successively.
In the insert culture system, a porous membrane permitting free
diffusion of molecules, but not that of cells, separates two
superimposed compartments. NHEPK are seeded into the upper
compartment and grown on the membrane in the presence of PR
medium. Under these conditions, they reach con¯uence within 2±
5 d, at which time (taken as time 0 of the experiment) the medium
of the upper, but not that of the lower, compartment is removed.
NHEPK are then cultured at the air±liquid interface for the rest of
the experiment and start to differentiate and to form a multilayered
epidermis-like structure, which is usually optimally organized by
days +7/+10. Afterwards, cultures begin to degenerate with
Table I. In vitro production of Tg10 MoAb by monolayer
cultures of engineered NHEPK
Transduced
Quantity of Tg10 antibodies in culture supernatants
(ng per 107 cells per 24 h : mean6standard deviation)
retroviral vector DK-SFM medium PR medium
CD 96 0 0
PM 130 17.562.9 32.5615
CD 167 15 60 27.568.7
A431.130.2 860 646 1003 6130
aNHEPK were retrovirally transduced and cultured under either proliferation-
favoring or differentiation/strati®cation-favoring conditions and compared to the
A431.130.2 cell line. In each individual infection experiment, 105 cells were used
and processed as described in Materials and Methods and the percentage of infected
cells was estimated to be 10%. Values represent the mean of four individual experi-
ments.
Figure 1. In vitro production of the Tg10 MoAb by engineered
NHEPK during neo-epidermis reconstruction by culture on
membrane inserts. Three 3 105 retrovirally transduced NHEPK (A)
or A431.130.2 cells (B) were seeded onto the membrane of an insert in a
culture well at day ±5 in the presence of PR medium both in the upper
and lower compartment. On the day considered as day 0, the medium
was removed from the upper compartment. The medium was then
changed every 2 d in the lower compartment for ELISA assay of Tg10.
(C) Assay of Tg10 in A431.130.2 cell culture supernatants contained in
the upper and the lower compartments of culture inserts. Values
represent the mean of two experiments.
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morphologic alterations and loss of architecture already visible
under the microscope by days +14/+15 (Mackenzie et al, 1993).
The data presented in Fig 1(A) are the average of two
experiments conducted with NHEPK previously transduced with
PM130 or CD167 with an ef®ciency of approximately 10%. In
both cases, the highest Tg10 production was observed before
removal of the culture medium from the upper compartment. In
the speci®c case of CD167, antibody production declined
progressively afterwards to become undetectable by day 10. In
that of PM130, a slight increase in antibody production could be
detected between day +2 and day +6 post-removal of the upper
compartment culture medium and was followed by a reduction to
undetectable level by day +16. In both situations, the reduction in
antibody release paralleled the deterioration of the culture as
monitored by visual examination under the microscope.
A similar experiment was conducted with A431.130.2 cells,
which also form three-dimensional structures under the culture
conditions used. A transient reduction in antibody production was
observed upon upper compartment culture medium removal.
Antibody production, however, remained sustained afterwards for
the whole duration of the experiment (24 d) (Fig 1B). This is
consistent with the fact that we observed no culture degeneration as
in the case of primary cultures for the duration of the experiment.
In this set of experiments, we monitored antibody release in both
the upper and the lower compartments on days ±5 and ±2 and
observed that Tg10 was essentially released into the upper phase
(Fig 1C). The need for repolarization of antibody secretion and
diffusion from the upper to the lower layers of the epidermis most
probably explains the transient decrease observed by day +2 with
A431.130.2 cells and NHEPK modi®ed with PM130.
In the second epidermis reconstitution assay we used, NHEPK
are seeded on a DED morti®ed by several freezing/thawing rounds
and then cultured in the presence of PR medium at the air±liquid
interface. Under these conditions, colonization of the dermis takes
approximately 5±7 d, at which time keratinocytes begin to form a
multilayered epidermis. The latter is fully reconstituted by days 7±
10 and contains approximately 4-fold more keratinocytes than the
amount seeded at the beginning of the experiment. Histologic
studies have previously shown that, under these conditions, neo-
epidermis is properly strati®ed and compartmentalized (ReÂgnier et
al, 1981; PrunieÂras et al, 1983) and shows most, if not all, of the
characteristics of skin terminal differentiation as testi®ed by the
presence of desmosomes, keratohyalin, and lamellar granules
(ReÂgnier et al, 1981). Moreover, such reconstituted epidermis is
longer-lived in vitro than cultures on inserts as the onset of
degeneration is usually not visible before 2 wk in culture
(Mackenzie et al, 1993). It is important, however, to stress that
there are signi®cant differences in the timing of the different phases
of epidermis reconstitution and degeneration according to (i) the
batch of NHEPK and (ii) the dermal substrate used.
We ®rst addressed whether antibody produced by genetically
modi®ed keratinocytic cells could transit through dermal substrates
and be released in the culture medium. To this aim, A431.130.2
cells were seeded on dermal substrates where they divide more
actively than primary NHEPK. The experiment presented in
Fig 2(A) shows a steady increase in Tg10 accumulation in the
culture medium re¯ecting cell proliferation from day 0 to day 11
followed by a plateau lasting until day 15. Experiments were then
conducted with CD167- and PM130-modi®ed NHEPK trans-
duced with an ef®ciency of 10%. Tg10 MoAb production in the
culture medium was monitored until day 15, at which time the
experiment was terminated. Tg10 was detected from day 3 post-
seeding in both series of experiments. It remained nearly constant
until day 15 in the case of CD167-modi®ed NHEPK but increased
four times between day 9 and day 15 for PM130-modi®ed cells
(Fig 2B). The difference in Tg10 production in the two experi-
ments could not be studied in detail but is probably explained by a
better proliferation followed by a better differentiation of PM130-
modi®ed NHEPK at the later stages of the culture.
In conclusion, our experiments showed that in vitro reconstituted
epidermis can produce an ectopic MoAb and secrete it towards the
basal skin layers. Variations in duration and ef®ciency of produc-
tion, however, were observed between the different experiments
conducted. They most probably re¯ect the intrinsic variability of
skin cell cultures due to the use of different batches of NHEPK
and/or dermal substrates.
Tg10 distribution in reconstituted epidermis on dermal
substrates The distribution of the Tg10-expressing keratinocytes
was then examined on cryosections of epidermis reconstructed for
15 d of culture on DED. A FITC-conjugated goat antimouse IgG
serum was used to detect cells expressing the Tg10 antibody. No
speci®c green ¯uorescence could be detected in control epidermis
reconstituted from NHEPK transduced with the void retroviral
vector pLXPXSN (Fig 3A). In contrast, NHEPK transduced with
the PM130 and CD167 retroviral vectors displayed an intense
¯uorescent signal that was exclusively cytoplasmic and were
essentially localized in the upper spinous and granular layers of
the epidermis (Fig 3B±F). Scoring of Tg10 MoAb-producing cells
on a series of serial slides indicated approximately 5% of positive
cells, which is a value slightly lower than, but of the same order of
magnitude as, the estimation of transduced cells at the beginning of
the experiment. No strong ¯uorescence was observed either in the
basement membrane zone or in the upper spinous layer.
Grafting of transduced keratinocytes to SCID mice We
next assessed whether genetically modi®ed epidermis reconstructed
in vitro can produce ectopic MoAb in vivo. To this aim, epidermis
reconstituted on DED substrates from NHEPK transduced with
either PM130 or CD167 were grafted subcutaneously to two
groups of four SCID mice as described in Rikimaru et al (1997) and
Tg10 release in the bloodstream was then assayed by ELISA for 2
mo. Mice grafted with DED only were used as negative controls.
In both series of experiments, antibody production was detect-
able as early as 3 d post-implantation and was sustained and
relatively stable for approximately 1 mo except for mouse 5, which
showed no detectable Tg10 MoAb for unelucidated reasons
(Fig 4A, B). Antibody levels were higher for PM130-modi®ed
Figure 2. In vitro production of the Tg10 MoAb by engineered
keratinocytes during neo-epidermis reconstruction on DED.
Three 3 105 A431.130.2 cells (A) or retrovirally transduced NHEPK (B)
were seeded onto a DED and maintained at the air±liquid interface for
15 d on PR medium. Tg10 MoAb contained in culture supernatants was
assayed by ELISA every 2 d. Values represent the mean of two
experiments.
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NHEPK (average of 190 ng per ml) than for CD167-modi®ed
NHEPK (average of 60 ng per ml), which is consistent with the
better MoAb production ef®ciency observed in in vitro cultures.
Thereafter, serum levels of antibodies started to decline to reach
basal levels by day 45. This decline is most probably due to
elimination of transduced producer cells upon migration from basal
to horny layers within the reconstituted epidermis, the latter
occurring in approximately 1 mo (see discussion below).
In conclusion, our experiments demonstrate the feasibility of
MoAb delivery into the bloodstream by grafting genetically
engineered in vitro reconstituted skin. They thus open a novel
possibility for exploiting the wide therapeutic potential of this class
of molecules (Glennie and Johnson, 2000) in gene/cell therapy
protocols. Systemic delivery of other proteins by genetically
engineered keratinocytes has already been reported (see Cao et al,
2000). All proteins except factor VIII (165 kDa) (Fakharzadeh et al,
2000) were of small size, however. Our data thus extend the notion
that molecules showing a high molecular weight (150 kDa range)
are not retained in engineered skin but can diffuse from skin
intercellular spaces towards the blood circulation, most probably via
lymphatic return.
Thus far, application of cutaneous gene transfer to humans, as
well as to animal preclinical models, has lagged far behind that of
visceral tissues because of the existence of natural cutaneous barrier
mechanisms resisting the insertion and/or stable expression of
foreign genetic material (Ghazizadeh and Taichman, 2000).
Consistent with this, serum antibody concentrations were modest
(in the 0.1 mg per ml range) and the duration of antibody
production was relatively limited in time (approximately 1 mo)
under the speci®c experimental conditions used in our study. These
two observations do not depart from most other reports dealing
with in vivo production of ectopic proteins such as factor IX
(Gerrard et al, 1993), growth hormone (Teumer et al, 1990), or
apolipoprotein E (Fenjves et al, 1989) by engineered keratinocytes
(also see Fenjves et al, 1994; Mathor et al, 1996; Cao et al, 2000;
Supp et al, 2000). It is reasonable, however, to assume that both the
level and the duration of MoAb production can be improved to a
large extent (Ghazizadeh and Taichman, 2000). In our experi-
ments, only a small fraction of cells (approximately 10%) were
actually transduced, most probably because of the low titers (104 cfu
per ml) of our retroviral vectors. Moreover, no more than 105
genetically modi®ed cells were implanted per mouse. It is thus
reasonable to assume that the grafting of more cells as well as the use
of higher titer vectors to increase the fraction of transduced cells
should a priori result in dramatically higher production yields. With
regard to the latter point, we have attempted to develop high titer
Figure 3. In situ localization of the Tg10-expressing keratinocytes in epidermis reconstructed on DED. At day 15 of culture, fully
reconstructed epidermis was processed for cryosections. Tg10 MoAb expression was assessed by immunohistologic staining using an FITC-conjugated
antimouse IgG and cell nucleus localization was determined using DAPI histochemical staining. (A) Section of control pLXPXSN-transduced epidermis
stained for Tg10 MoAb. (B) Section of CD167-transduced epidermis at low magni®cation stained for Tg10 MoAb. (C) Section of CD167-transduced
epidermis at a higher magni®cation stained for Tg10 MoAb. (D) Same section as in (C) but stained with DAPI. (E) Section of PM130-transduced
epidermis at high magni®cation stained for Tg10 MoAb. (F) Same section as in (E) but stained with DAPI. The arrows indicate Tg10-expressing
keratinocytes transduced with the CD167 (B±D) or PM130 (E, F) vectors.
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antibody-producing MLV-based vectors using a variety of
approaches with, thus far, no success, for unelucidated reasons.
Developing such vectors thus remains an important issue in
ef®cient skin-based genetic immunotherapy aiming at systemic
MoAb delivery. Alternatively, vectors capable of integration in the
cell genome, and thus transmissable to progeny cells, such as
lentiviruses and adeno-associated viruses (Braun-Falco et al, 1999;
Ghazizadeh and Taichman, 2000) might also prove to be better
tools to achieve the same goal. It must also be taken into
consideration that murine leukemia LTRs are relatively poor
transcription promoters after retroviral integration, as could be
estimated by low Tg10 mRNA accumulation in a variety of cells
(NoeÈl et al, 1997), and are often turned off in vivo (Palmer et al,
1991), including in the case of keratinocytes (Choate and Khavari,
1997). Although transcriptional shut-off is not systematic, as Levy et
al (1998) have reported sustained expression of chick b1 integrin by
retrovirally transduced keratinocytes grafted to nude and athymic
mice for at least 4 mo, transcription from an internal promoter,
ideally regulatable to stop MoAb production in case the treatment
must be terminated, might provide higher and longer term
expression, as has been demonstrated in the case of genetically
modi®ed ®broblasts (Scharfmann et al, 1991).
Finally, the short-term expression of MoAb in our experiments
has most probably been brought about by failure to target
epidermal stem cells, although we cannot formally rule out that
loss of expression was brought about by implantation of grafts
subcutaneously and not at the normal anatomic location.
Supporting this interpretation, immunochemical analysis of genet-
ically modi®ed epidermis reconstituted in vitro showed that
transduced cells were mostly, if not exclusively, localized in
intermediate layers and not in the basal layer, which constitutes the
reservoir of stem cells. Although recent work by Tani et al (2000)
has shown that skin stem cells are dividing slowly in vivo in mice, it
is unlikely that lack of infection was due to poor cell division
activity as Kolodka et al (1998) have shown that keratinocyte stem
cells can persist in culture where they can undergo retroviral
transduction at high ef®ciency provided that high titer viral stocks
are used. This stresses again that our present lack of high titer
antibody-producing vectors, whatever their nature, most probably
constitutes a major hurdle to ef®cient long-term skin-based genetic
immunotherapies. Experiments are currently under way to over-
come this limitation.
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